– EQT XI has agreed to acquire QIAGEN N.V. through an all-cash voluntary public takeover offer of €46.50 per share, valuing the life sciences and diagnostics company at approximately €10.8 billion in enterprise value, or $12.1 billion, including around $1.1 billion in net debt.
– The offer represents a 40.3% premium to QIAGEN’s closing share price of €33.15 on 8 July 2026, before reports of private equity takeover interest, and a 46.9% premium to its three-month volume-weighted average share price of €31.66.
– The acquisition vehicle, Crown NL Bidco B.V., is indirectly controlled by EQT XI, alongside co-investors Luxinva, a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA), and CPP Investment Board Europe Inc., a subsidiary of CPP Investments | Investissements RPC.
– QIAGEN’s Supervisory Board and Managing Board unanimously concluded that the transaction represents the best path forward following a comprehensive strategic review and discussions with strategic and financial parties. The boards believe private ownership will provide greater flexibility to invest for the long term while delivering attractive, certain cash value to shareholders.
– Stephen H. Rusckowski, Chairman of QIAGEN’s Supervisory Board, said: “This transaction offers shareholders compelling value while positioning QIAGEN for its next phase of development under private ownership.”
– Jonathan Pratt, CEO of QIAGEN, said: “Under private ownership, we can move faster and have greater freedom to put resources behind the most attractive opportunities that align best with our long-term strategy.”
– Roland Sackers, CFO of QIAGEN, said: “This agreement provides our shareholders with an attractive premium while giving QIAGEN a strong partner that shares our strategic priorities and vision for the future.”
– Matteo Thun-Hohenstein, Partner at EQT, said: “We are proud to partner with QIAGEN’s highly talented and capable employees to further invest in QIAGEN’s continued product innovation and growth.” EQT highlighted QIAGEN’s strong market positions, respected brands and technical expertise in life sciences and diagnostics.
– Michael Bauer, Global Co-Head of Healthcare at EQT, said: “This is a landmark transaction for EQT and a powerful reflection of the deep sector understanding, investment experience and network of expertise we have built over the last three decades.”
